Does the Addition of Lamivudine to Peginterferon a-2a sustain Response Rates in Patients with HBeAG Negative Hepatitis B?
- Cooksley, G.
Publication date
January 2005
DOI Publisher
Springer Science and Business Media LLCAbstract
BACKGROUND HEPATITIS B e ANTIGEN (HBeAg)-NEGATIVE CHRONIC HEPATITIS B has a poor prognosis because sustained remission is hard to achieve with current treatments. The optimal therapy or combination of therapies for this condition has not been determined. OBJECTIVES To determine the efficacy and safety of peginterferon α-2a monotherapy, peg interferon α-2a in combination with lamivudine, and lamivudine monotherapy for the treatment of HBeAg-negative chronic hepatitis B
Add to ORKG